Small cell lung cancer.

Published

Journal Article

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

Full Text

Duke Authors

Cited Authors

  • Kalemkerian, GP; Akerley, W; Bogner, P; Borghaei, H; Chow, LQ; Downey, RJ; Gandhi, L; Ganti, AKP; Govindan, R; Grecula, JC; Hayman, J; Heist, RS; Horn, L; Jahan, T; Koczywas, M; Loo, BW; Merritt, RE; Moran, CA; Niell, HB; O'Malley, J; Patel, JD; Ready, N; Rudin, CM; Williams, CC; Gregory, K; Hughes, M; National Comprehensive Cancer Network,

Published Date

  • January 1, 2013

Published In

Volume / Issue

  • 11 / 1

Start / End Page

  • 78 - 98

PubMed ID

  • 23307984

Pubmed Central ID

  • 23307984

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Language

  • eng

Conference Location

  • United States